Fig. 3. Effects of SFN in mice with diet-induced diabetes.

Slides:

Advertisements

Similar presentations

Figure Legend: From: High-Fat Diet–Induced Retinal Dysfunction

Advertisements

Effects of highly concentrated SFN provided as BSE in T2D patients

Fig. 2. Effects of SFN in mouse hepatocytes and in rat models of diet-induced glucose intolerance. Effects of SFN in mouse hepatocytes and in rat models.

Basic design concept of human mimetic humanoid.

Three different types of transfer functions with a codomain of [0,1].

TPAD training protocol.

Deficiency in myeloid-resident NRP1 affects systemic metabolism.

Platelets are required for hFcγRIIA-induced anaphylaxis.

NRP1-expressing myeloid cells influence adipocyte hypertrophy, development of fatty liver, and CLSs. NRP1-expressing myeloid cells influence adipocyte.

Tukey boxplots overlaid on data points from objective and subjective measures, displaying results from study 1. Tukey boxplots overlaid on data points.

Fig. 6 Transmissibility of adiposity from humanized mice to germ-free recipients. Transmissibility of adiposity from humanized mice to germ-free recipients.

Fig. 7 Correlation of NHP and human ISGs.

Fig. 6 In utero injection of inflammatory cytokines or adoptive transfer of activated T cells leads to pregnancy loss. In utero injection of inflammatory.

Hyperinsulinemic-euglycemic clamps revealed that obese TPL2KO mice have an improved insulin sensitivity compared with obese WT mice. Hyperinsulinemic-euglycemic.

Fig. 5 Quantitative assessment of the efficacy of the tissue-engineered implant to heal the TMJ disc defect. Quantitative assessment of the efficacy of.

Cell viability tests. Cell viability tests. SEM images of (A) MC3T3-E1 cells and (B) MSCs on days 1, 3, and 5 of culture. (C) Survival rates of MC3T3-E1.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Fig. 2 Preserved long-term functionality of the TEHVs over 1-year follow-up as assessed by ICE and cardiac MRI flow measurements. Preserved long-term functionality.

Fig. 6. Nontaxane chemotherapies induce TMEM-dependent prometastatic changes in the breast cancer microenvironment. Nontaxane chemotherapies induce TMEM-dependent.

Microrobots with different cell-carrying capacities under different grid lengths (lg) and burr lengths (lb). Microrobots with different cell-carrying capacities.

Fig. 1 Examples of experimental stimuli and behavioral performance.

Fig. 5. In vivo characterization of adipogenesis by CT.

A: Chemical structure of pterosin A

Fig. 2 HHKO mice exhibit improved glucose tolerance by increasing plasma incretin levels and insulin secretion. HHKO mice exhibit improved glucose tolerance.

Fig. 4 Deletion of hepatocyte HIF-2α does not affect obesity-induced glucose, glucagon, and insulin intolerance. Deletion of hepatocyte HIF-2α does not.

Fig. 3 Glucose- and structure-dependent insulin release.

Fig. 3 Scan rate effects on the layer edge current.

Hepatic PPARγ deficiency impairs the SCFA-induced reduction in hepatic steatosis. Hepatic PPARγ deficiency impairs the SCFA-induced reduction in hepatic.

Fig. 3. Increased expression of exhaustion markers and apoptosis markers on CAR8 cells in the presence of TCR antigen. Increased expression of exhaustion.

Fig. 4 Administration of BMS to mice inhibits autoimmune-relevant pharmacodynamic endpoints driven by IL-12 and IFNα. Administration of BMS

Fig. 3 BMS blocks functional responses in primary immune cells driven by IL-23 and IL-12. BMS blocks functional responses in primary immune.

BMS blocks functional responses in primary immune cells driven by IFNα

Fig. 2. Effects of SFN in mouse hepatocytes and in rat models of diet-induced glucose intolerance. Effects of SFN in mouse hepatocytes and in rat models.

Fig. 5 Treatment with BMS (PO BID) protects from wasting and colitis in two SCID mouse models. Treatment with BMS (PO BID) protects from.

Fig. 3 Local Maraba treatment of TNBC tumors provides long-term systemic protection. Local Maraba treatment of TNBC tumors provides long-term systemic.

Fig. 1 Average contribution (million metric tons) of seafood-producing sectors, 2009–2014. Average contribution (million metric tons) of seafood-producing.

Fig. 5 A holistic formula TNTL targeting SBP2 in ATMs improved insulin resistance in obese mice. A holistic formula TNTL targeting SBP2 in ATMs improved.

Fig. 3 Loss of SBP2 in obesity exacerbated insulin resistance and adipogenesis. Loss of SBP2 in obesity exacerbated insulin resistance and adipogenesis.

Contrast agent uptake for the four different groups of MMA mice

Representative CT and PET/CT images of three patients with NSCLCs

Fig. 1. The HCN channel blocker ivabradine (IVA) is analgesic in a mouse model of type 1 diabetes. The HCN channel blocker ivabradine (IVA) is analgesic.

Fig. 1 Crohn’s disease association within the LRRK2 locus.

Pharmacological targeting of CDs promotes response to KRASG12C inhibition in vivo. Pharmacological targeting of CDs promotes response to KRASG12C inhibition.

Fig. 4 Overexpression of SBP2 improved insulin sensitivity and suppressed adipogenesis in obese mice. Overexpression of SBP2 improved insulin sensitivity.

Fig. 4 Dox-CBD-SA treatment shows reduced toxicity.

Fig. 4 Effects of hematopoietic restoration of TLR9 on adipose tissue inflammation and insulin resistance. Effects of hematopoietic restoration of TLR9.

Fig. 5. Vascularization of human liver seed grafts.

Fig. 3. Human liver tissue seed graft function.

Tissue architecture affects function of expanded liver seed grafts

Fig. 3 Mmp-2−/− mice are protected from obesity and leptin resistance.

Fig. 2 Neonatal ZIKV infection induces seizures in young mice and increases susceptibility to chemically induced seizures in adult mice. Neonatal ZIKV.

Bio-AMS enhances the activity of rifampicin and ethambutol in vitro

In vivo prophylactic and therapeutic efficacy of C12G6 in mice

Fig. 2. Human liver tissue seed grafts expand after host liver injury.

Fig. 1. GDF15 is up-regulated with obesity, and AAV-GDF15 improves metabolic parameters in DIO mice. GDF15 is up-regulated with obesity, and AAV-GDF15.

Fig. 2 Increasing KLF17, CDH1, and LASS2 expression reduced malignant progression and promoted apoptosis of tumor cells. Increasing KLF17, CDH1, and LASS2.

Fig. 5. High burdens of AA signature mutations and predicted immunogenicity in Taiwan HCCs. High burdens of AA signature mutations and predicted immunogenicity.

Effects of highly concentrated SFN provided as BSE in T2D patients

Fig. 1. Construction of human liver seed grafts.

AV3 potentiates the effect of gemcitabine in the PDX model in mice

Fig. 7 BEL immune response.

Fig. 4 Single-particle contact angle measurements.

Fig. 5 DDO-5936 dose-dependently impairs the growth of xenografted HCT116 cells in nude mice. DDO-5936 dose-dependently impairs the growth of xenografted.

Fig. 2 Comparison between the different reflective metasurface proposals when θi = 0° and θr = 70°. Comparison between the different reflective metasurface.

Fig. 6 TNF-α neutralization prevents ZIKV-induced seizures in mice.

Fig. 4 Gallium increases P. aeruginosa sensitivity to peroxides.

Meningeal γδ T cell homeostasis is independent of inflammatory signals

Fig. 6 Pharmacologic alterations of β-AR signaling regulate cardiomyocyte abscission and endowment. Pharmacologic alterations of β-AR signaling regulate.

Fig. 3 Evaluation of PTMAO immunogenicity.

CSGG-induced iTreg cells are capable of suppressing intestinal inflammation. CSGG-induced iTreg cells are capable of suppressing intestinal inflammation.

Presentation transcript:

Fig. 3. Effects of SFN in mice with diet-induced diabetes. Effects of SFN in mice with diet-induced diabetes. (A) IPGTT in male C57BL/6J mice fed a low-fat control diet or 60% HFD for 14 weeks treated with vehicle or SFN (0.5 or 10 mg/kg per day) for 4 weeks (n = 7 to 8 in each of the HFD groups, n = 5 to 6 in each of the control diet groups). (B) IPITT data from the mice in (A). (C) Triglyceride content in extracted liver tissue from the mice treated as in (A). (D) Gluconeogenetic rate in male C57BL/6J mice fed a 60% HFD for 12 weeks and treated with vehicle or SFN (10 mg/kg per day) for 4 weeks (n = 8 per group). The bars show data from the entire groups (average weight 40 ± 2 g for vehicle-treated and 39 ± 1 g for SFN-treated) as well as data for the three mice in each group with the highest body weight (heavy; weight of 42, 42, and 47 g for vehicle-treated and 39, 40, and 48 g for SFN-treated compared to an average weight of 38 ± 1 g for vehicle-treated and 37 ± 0.2 g for SFN-treated nonheavy mice). (E) Rate of disappearance of glucose (Rd) during clamp, reflecting whole-body insulin-stimulated glucose uptake, for the same mice as in (D). Data are means ± SEM. *P < 0.05; **P < 0.01. Annika S. Axelsson et al., Sci Transl Med 2017;9:eaah4477 Copyright © 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.